George Nageeb

Immunotherapy for Glioma: A compartmental framework for resistance and rational combination design

Diffuse gliomas remain among the least responsive solid tumors to immunotherapy despite a compelling rationale for immune surveillance of infiltrative disease. The clinical record—negative phase III checkpoint blockade trials, limited durability of single-antigen vaccines, and im...